Publication Name	World Journal of Clinical Cases
Manuscript ID	101981
Country	China

Received	2024-10-03 15:06
Peer-Review Started	2024-10-03 15:06
To Make the First Decision
Return for Revision	2024-11-25 10:38
Revised	2024-12-14 15:02
Second Decision	2024-12-26 02:35
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-12-27 10:29
Articles in Press	2024-12-27 10:29
Publication Fee Transferred	2024-12-17 04:51
Edit the Manuscript by Language Editor	2025-01-04 01:27
Typeset the Manuscript	2025-01-13 01:26
Publish the Manuscript Online	2025-01-15 03:58

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Medical Informatics
Manuscript Type	Case Report
Article Title	Vitiligo-like rash in a patient with lung cancer caused by sintilimab: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Xiao-Ming Mao and Wei-Hua Wang
Funding Agency and Grant Number
Corresponding Author	Wei-Hua Wang, Department of Respiratory and Critical Care Medicine, Jiangshan People’s Hospital, No. 9 Hangbengshan Road, Jiangshan 324100, Zhejiang Province, China. mxm0077@163.com
Key Words	Lung cancer; Vitiligo; Immune checkpoint inhibitor; Sintilimab; Case report
Core Tip	The article presents a case study of a 63-year-old male with non-small cell lung cancer treated effectively with chemotherapy and immunotherapy, despite developing immune-related skin adverse events manifesting as a vitiligo-like rash. The treatment with sintilimab, a programmed death 1 inhibitor, resulted in tumor regression and highlighted the need for further research into the prognostic significance and mechanisms of vitiligo-like rash in lung cancer patients undergoing immunotherapy.
Publish Date	2025-01-15 03:58
Citation	<p>Mao XM, Wang WH. Vitiligo-like rash in a patient with lung cancer caused by sintilimab: A case report. <i>World J Clin Cases</i> 2025; 13(14): 101981</p>
URL	https://www.wjgnet.com/2307-8960/full/v13/i14/101981.htm
DOI	https://dx.doi.org/10.12998/wjcc.v13.i14.101981

Full Article (PDF)	WJCC-13-101981-with-cover.pdf
CARE Checklist–2016	101981-CARE-Checklist-2016.pdf
Manuscript File	101981_Auto_Edited_020010.docx
Answering Reviewers	101981-answering-reviewers.pdf
Audio Core Tip	101981-audio.m4a
Conflict-of-Interest Disclosure Form	101981-conflict-of-interest-statement.pdf
Copyright License Agreement	101981-copyright-assignment.pdf
Signed Consent for Treatment Form(s) or Document(s)	101981-informed-consent-statement.pdf
Non-Native Speakers of English Editing Certificate	101981-non-native-speakers.pdf
Peer-review Report	101981-peer-reviews.pdf
Scientific Misconduct Check	101981-scientific-misconduct-check.png
Scientific Editor Work List	101981-scientific-editor-work-list.pdf
CrossCheck Report	101981-crosscheck-report.pdf